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Abstract 
Introduction: Patients with lung cancer who harbor multiple pulmonary sites of disease have been 
challenging to classify; a subcommittee of the IASLC Staging and Prognostic Factors Committee was 
charged with developing proposals for the 8th edition TNM classification to address this issue. 
Methods: A systematic literature review and IASLC database analysis was performed to develop 
proposals for revision in an iterative process involving multispecialty international input and review. 
Results: Details of the evidence base are summarized in other papers. Four patterns of disease are 
recognized; the clinical presentation, pathologic correlates and biologic behavior of these suggest specific 
applications of TNM classification rules. First, it is proposed that second primary lung cancers be 
designated with a T, N and M category for each tumor. Second, tumors with a separate tumor nodule of 
the same histologic type (either suspected or proven) should be classified according to the location of the 
separate nodule relative to the index tumor – T3 for a same-lobe, T4 for a same-side (different lobe), and 
M1a for an other-side location – with a single N and M category. Third, multiple tumors with prominent 
ground glass (imaging) or lepidic (histology) features should be designated by the T category of the 
highest T lesion, the number or “m” in parentheses (#/m) to indicate the multiplicity, and a collective N 
and M category for all. Finally, diffuse pneumonic-type lung cancers are proposed to be designated by 
size (or T3) if in one lobe, T4 if involving multiple same-side lobes, and M1a if involving both lungs with 
a single N and M category for all areas of involvement. 
Conclusion: We propose to tailor TNM classification of multiple pulmonary sites of lung cancer to 
reflect unique aspects of 4 different patterns of presentation. We hope this will lead to more consistent 
classification, clarity in communication, and facilitate further research in the nature and optimal treatment 
of these entities. 
 
Introduction 
The 7th edition of the tumor, node and metastasis (TNM) classification for lung cancer contained 
some ambiguity with respect to classification of lung cancer with multiple pulmonary sites of 
involvement. Surveys of experts reveal that there was marked variability in how different people would 
classify particular tumors,1, 2 thus undermining the primary goal of TNM classification, which is to 
provide a nomenclature for tumor extent that creates homogeneous cohorts of tumors. Furthermore, the 
heterogeneity resulting from this variability hampers the ability to interpret research studies.  
Defining homogeneous groups is particularly important among patients with multiple pulmonary 
sites of lung cancer, as several patterns of presentation are associated with multiple lesions. These exhibit 
marked differences in biologic behavior, including survival and recurrence patterns. The heterogeneity in 
classification since the 7th edition of TNM classification arises both from a lack of clear distinction 
between disease entities as well as ambiguity about how to apply stage classification rules to these 
patients. 
Second primary lung cancers have long been recognized by the TNM system although little detail 
was provided regarding how this diagnosis should be established. Separate tumor nodules were classified 
as M1 until 1993, when they were defined as raising the T category by 1 when in the same lobe as the 
primary and as T4 if in a different lobe. In 1997 a separate tumor nodule was classified as T4 if in the 
same lobe and M1 if in a different lobe (ipsi- or contralateral). In 2010 these were reclassified as T3 for a 
same-lobe separate nodule (and the term “satellite” nodule for such lesions was abandoned), as T4 for an 
ipsilateral different-lobe nodule and as M1a for a contralateral nodule. Moreover, previous editions of 
TNM provided little guidance on what constitutes a separate tumor nodule until the 7th edition, in which 
the language has turned out to be variously interpreted.1, 2 Furthermore, the 7th edition contained only 
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vague mention of ground glass or lepidic lesions, and predated the 2011 definition of adenocarcinoma 
subtypes.3, 4 
To provide better clarity for the 8th edition of TNM classification, an international subcommittee 
of experts conducted a comprehensive review of relevant data. This was used to identify distinct patterns 
of disease and to develop criteria to categorize lung cancer with multiple pulmonary sites of involvement 
accordingly. Furthermore, the subcommittee formulated clear instruction on how to apply TNM 
classification rules to each pattern of disease, taking into account the particular issues that each one 
presents. The full scope of this process is detailed in additional papers.5-7 This paper summarizes the 
recommendations for lung cancer with multiple pulmonary sites of involvement in one document. 
Four patterns of presentation are associated with multiple pulmonary sites of lung cancer (Figure 
1). First, patients can present with second primary lung cancers. The demographic characteristics, 
outcomes and recurrence patterns for each tumor are similar to that of single “typical” lung cancers 
according to the stage and histologic type. Second, some patients with a solid primary lung cancer have 
one or more separate solid tumor nodule(s) of the same histologic type (referred to as intrapulmonary 
metastasis in the pathology community). The behavior of these tumors is similar to that of a similar 
solitary tumor; outcomes are slightly inferior and impacted by how they are treated.  A third pattern of 
disease involves patients presenting with multiple lung cancer nodules with prominent ground glass or 
lepidic (GG/L) features. This group has different demographic characteristics, excellent outcomes, and 
infrequent recurrences outside the lung parenchyma. A fourth pattern of disease involves a form of lung 
cancer that is radiologically similar to a pneumonia (so-called pneumonic-type of lung cancer). 
Extrathoracic and nodal involvement is infrequent, but prognosis is distinctly worse than for patients with 
multiple GG/L nodules.  
Methods 
To develop proposals for revision of the classification of lung cancers with multiple pulmonary 
sites of involvement, an international multidisciplinary subcommittee of the International Association for 
the Study of Lung Cancer (IASLC) Staging and Prognostic Factors committee (SPFC) was formed (i.e. 
the authors of this paper). This group conducted a comprehensive review of the relevant literature. Details 
of this process and results are provided in a series of review papers;5-7 a summary of this data is provided 
in the next section of this paper. In addition, the IASLC database from 1999-2010 was analyzed regarding 
separate tumor nodules (this was the only pattern of disease for which there was sufficient data in the 
database). This evidence was then used in an iterative process to develop recommendations. These 
documents were critically evaluated by an extended workgroup (appendix) in addition to review and 
eventual endorsement by the entire SPFC 
Brief Summary of Evidence Review 
Second Primary Lung Cancers 
A different histologic type is generally sufficient to establish 2 malignant pulmonary lesions as 
separate primary cancers, provided adequate tissue is available. Similarly, different appearance by a 
detailed histologic assessment (proportion of subtypes, grade, cytologic and stromal features, etc.) of 
resected specimens can establish tumors as second primary cancers. However the same (or predominant) 
histologic type does not by itself clearly establish that the lesions are manifestations of the same tumor. 
Historical studies, clonality studies and outcomes studies indicate that the large majority of second 
cancers of the same histologic type are likely to be second primary lung cancers.6 Similarly, the same 
morphologic appearance by a more detailed histologic assessment as noted above should not be taken by 
itself as clear evidence that two lesions are manifestations of the same tumor; it is only suggestive that 
two lesions may be related.6 
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Assessment of biomarkers (driver gene mutations) is only suggestive, as there is a substantial rate 
of discordance among different samples of the same tumor and concordance among clearly separate 
tumors.6 Thus, mutational profiling should not be considered definitive and must be considered together 
with other information. More detailed genetic assessments (comparative genomic hybridization, Next-
Gen sequencing) are promising but not sufficiently studied or standardized, and are complex to use in 
routine clinical practice.6 
Separate Tumor Nodules (Intrapulmonary Metastasis) 
The IASLC database for the 7th (1990-1999) and 8th edition (1999-2010) included a small 
proportion of patients who were recorded as having a separate malignant nodule (2.5% and 3.5%, 
respectively).8, 9 It appears that these patients primarily fit a pattern of disease consisting of a typical 
primary lung cancer (i.e. a solid mass) with a separate solid tumor nodule of the same histologic type 
(rarely more than one). The outcomes of these patients in the IASLC database analysis was consistent 
with those gathered in a systematic literature review.5  
Among clinically staged patients, overall survival (OS) decreased progressively by location of the 
separate tumor nodule relative to the primary tumor (same lobe > same lung [different lobe] > other 
lung),5 consistent with the analysis for the 7th edition. However, OS seems to have been primarily 
impacted by the treatment given; there was no difference in OS by separate tumor nodule location among 
only surgically managed patients or among non-surgically managed patients. Other confounding factors 
include varying proportions of incidentally discovered nodules (not identified preoperatively) and 
selection factors leading some patients to be managed surgically and others non-surgically. Because of an 
inability to separate the influence of these various factors, the TNM classification of the 7th edition for 
separate tumor nodules was maintained.  
Multifocal Lung Adenocarcinoma with Ground Glass/Lepidic Features) 
An increasing number of lung cancer patients are encountered that have multiple sub-solid 
nodules (either pure ground glass or part-solid) on CT examination. The pathologic correlates of this 
appearance are lepidic predominant adenocarcinoma (LPA), minimally invasive adenocarcinoma (MIA), 
or adenocarcinoma in situ (AIS) with or without other subtypes of adenocarcinoma as lesser components.3 
The ground glass and solid components seen by CT generally correspond to lepidic and invasive 
histologic patterns, respectively. The nature of these lesions and their relationship to one another are not 
yet fully understood; they are viewed as separate tumors with an in situ or invasive component that has 
arisen from a predominant non-invasive component. Clonality studies comparing multiple such tumors in 
the same patient are conflicting.7 
The patients with such lung adenocarcinomas that present as multiple nodules with ground glass 
features have a decreased propensity for nodal or systemic spread and an increased propensity to develop 
additional sub-solid cancers.7 Furthermore, they often exhibit a more indolent behavior.7 There are often 
numerous additional GG/L foci, and the patients are often women and non-smokers. These lesions are 
easy to recognize clinically (by CT imaging) and pathologically (prominent lepidic component). Thus this 
pattern of disease has many distinct features. 
Pneumonic-Type of Lung Adenocarcinoma 
A subset of patients exhibits a diffuse consolidative pattern (“pneumonic-type” of lung 
adenocarcinoma) without proximal bronchial obstruction.10-12 There are typically areas of ground glass as 
well as solid consolidation. This pattern of clinical presentation typically correlates with invasive 
mucinous adenocarcinoma,4 which characteristically show a goblet and/or columnar cell morphology with 
abundant intracytoplasmic mucin. Although invasive mucinous adenocarcinoma often shows lepidic 
predominant growth, extensive sampling usually reveals invasive foci, sometimes with desmoplastic 
stroma. Invasive mucinous adenocarcinoma may show a heterogeneous mixture of adenocarcinoma 
subtypes. Surrounding alveolar spaces often fill with mucin. This heterogeneous histologic appearance is 
frequently similar throughout areas of involvement in a particular patient. A detailed study of a patient 
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with diffuse pneumonic adenocarcinoma suggested different clonality in each of the 5 lobes examined;13 
it is controversial how to interpret this case. The majority of these patients have an invasive mucinous 
adenocarcinoma, the rest are mixed or non-mucinous adenocarcinomas.7  
These patients typically present without nodal or systemic metastases despite diffuse pulmonary 
involvement; the occasional use of double lung transplantation as a treatment underscores this.14-16 
Although the rate of progression is often slow, survival is markedly worse than for patients with GG/L 
tumors. Thus, although there are some similarities between the multiple GG/L pattern of disease and the 
pneumonic pattern of disease (e.g. ground glass and lepidic components, decreased propensity for nodal 
and systemic involvement), there are sufficient differences to consider this a distinct pattern of disease. 
Second Primary Lung Cancers 
Description 
Criteria to identify 2 tumor foci as either separate primary tumors or related (i.e. arising from a 
single source) are summarized in Table 1. Some criteria are generally definitive by themselves, while 
others are suggestive but must be considered together with all available information. The relative weight 
to give to a particular suggestive observation will depend on several factors such as the degree of 
similarity or difference, the reliability of the assessment, and what data is available (e.g. the extent of 
prior imaging available, tissue may consist of a limited biopsy or resection specimens). It is easier to 
define criteria that identify 2 malignancies as separate than criteria that conclusively establish that the 
tumors are identical. Ideally, a decision to classify 2 (or more) lesions as synchronous primary cancers or 
2 identical foci of a single cancer should be based on the judgment of an experienced multidisciplinary 
team, taking into account all factors (e.g. clinical, imaging, histological etc.). 
Proposed TNM Classification 
Two (or more) synchronous primary lung cancers should be classified separately, each with a T, 
N, and M descriptor, i.e. a T, N, and M for one tumor and another T, N and M for the other tumor. For 
example, a patient with a 2.2 cm squamous cell cancer in the right upper lobe, a 3.5 cm adenocarcinoma 
in the left upper lobe with adenocarcinoma in a L11 node by endobronchial ultrasound aspiration, and no 
other evidence of nodal or systemic metastases should be classified as having a T1c N0 M0 squamous cell 
cancer and a T2a N1 M0 adenocarcinoma. 
This TNM classification of tumors judged to be 2nd primary lung cancers should be applied to 
both synchronous or metachronous 2nd primary lung cancers, and whether the 2 primary tumors are in 
different lungs, different lobes or in the same lobe. Furthermore, this classification should be applied to 
synchronous primary lung cancers recognized clinically or grossly as well as those only recognized on 
pathologic examination.  
 
Separate Tumor Nodule (Intrapulmonary Metastasis) 
Description 
Patients should be classified as having separate tumor nodule(s) when there is a “classic” lung 
cancer (i.e. solid, spiculated) and one (or more) solid separate lung nodules, either presumed (clinical 
staging) or proven (pathologic staging after comprehensive histologic assessment) to be metastatic from 
the primary lung cancer; criteria are summarized in Table 2. Typically there is one additional nodule, 
although there may be more than one. 
However, the designation of separate tumor nodule(s) should not be used if it is judged that the 
patient has synchronous primary lung cancers (as defined in the previous section). Furthermore, the 
designation of separate tumor nodule(s) should not be used in patients with multifocal GG/L lung 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
adenocarcinoma (multiple nodules with ground glass features or multiple foci of LPA, MIA, AIS – see 
next section).  
Proposed TNM Classification 
The TNM classification of a separate tumor nodule(s) (of the same histologic type) is assigned 
based on the location of the nodule relative to the primary tumor site. If it is in the same lobe, the tumor is 
designated as T3, in the same lung (different lobe) as T4, and if in the contralateral lung as M1a.5 This 
applies regardless of whether there is involvement of nodal sites or distant (extrathoracic) sites. In other 
words, such separate tumor nodules in the lung determine the T category even when there are many sites 
of extrathoracic metastases (but the tumor would be classified as M1b or M1c because of the 
extrathoracic metastases). Finally, this classification should be applied to separate tumor nodules 
recognized clinically or grossly as well as those only recognized on pathologic examination. 
 
Multifocal Lung Adenocarcinoma with Ground Glass/Lepidic Features) 
Description 
Patients with this pattern of disease present with multiple sub-solid tumor nodules (either pure 
GGN or part-solid). A GGN is a focal nodular area of increased lung attenuation on CT, including both 
well and poorly defined lesions, through which normal parenchymal structures, including airways and 
vessels, can be visualized.17 A sub-solid nodule can be either purely ground glass or a part-solid nodule 
(usually still >50% ground glass but with a solid component). (Note that a radiographically solid 
appearance and the specific histologic subtype of solid adenocarcinoma denote different things.)4 
Tumors should be categorized as multifocal lung adenocarcinoma if there is a malignant sub-solid 
nodule (either suspected or proven) and other nodules with ground glass features, regardless of whether 
the other lesions are biopsied or not, and if biopsied, regardless of whether they are shown to be LPA, 
MIA or AIS (Table 3).7 Frequently multifocal lung adenocarcinoma patients have 3-10 (or more) nodules.  
This categorization should also apply to patients in which a subsolid lesion appears to have arisen from a 
GGN (or a lepidic background), but in which the lesions has become >50% solid (or invasive), provided 
that other nodules with ground glass features are present as well.  
Multifocal lung cancer is essentially only seen as a manifestation of adenocarcinoma. The 
pathologic designation of multifocal lung cancer should be used when there are multiple resected lesions 
that are either LPA, MIA or AIS with or without other subtypes of adenocarcinoma as lesser components. 
It is appropriate to combine pathologic identification of one focus of LPA, MIA or AIS with clinical 
information that there are other, non-resected sub-solid nodules (e.g. in other lobes). The GG/L category 
should be used whether a detailed histologic assessment (i.e. proportion of subtypes, etc.) shows the 
lesions to have a matching appearance or to be different.  
The multifocal GG/L lung adenocarcinoma designation should not be applied to patients with 
multiple GGNs which are thought to all represent benign or preneoplastic lesions (i.e. AAH). Pure GGNs 
≤5 mm and foci of AAH should not be counted, although such lesions are often present in patients with 
multifocal GG/L adenocarcinoma. 
Proposed TNM Classification 
Multifocal GG/L adenocarcinoma should be classified by the T category of the lesion with the 
highest T with the number of lesions (#) or simply (m) for multiple indicated in parentheses, and an N and 
M category that applies to all of the multiple tumor foci collectively – e.g. T1a(4) N0 M0. The apparent 
decreased propensity for nodal and distant metastases and increased propensity to additional lung lesions 
supports the concept of a single N and M for all of the pulmonary lesions. The lesion size is determined 
by the largest diameter of the solid component (by CT) or the invasive component under the microscope; 
a designation of Tis should be used for AIS and T1a(mi) for MIA.18 
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The T(#/m) multifocal classification should be applied equally whether the lesions are in the same 
lobe, or different ipsilateral or contralateral lobes. Furthermore, the T(#/m) multifocal classification 
should be applied to both grossly recognizable lesions as well as those that are only discovered on 
pathological examination (microscopically or otherwise). 
Diffuse Pneumonic-Type of Lung Adenocarcinoma 
Description 
The category of a pneumonic-type of lung adenocarcinoma refers to tumors with a consolidative 
pattern by CT (in the absence of an obstructed bronchus), either confined to a particular area (segment or 
lobe) or diffusely in the lung parenchyma (Table 4). The parenchymal borders of the tumor are infiltrative 
and typically not well demarcated. The tumor may be confined to one region (e.g. segment, lobe) or 
involve several regions (either confluent or separated) or diffusely involve both lungs. The involved areas 
typically are a mixture of ground glass and dense consolidation with frequent air bronchograms 
radiologically and lepidic and invasive foci microscopically. The majority of pneumonic-type of lung 
cancers are invasive mucinous adenocarcinomas, the rest are either non-mucinous or mixed mucinous and 
nonmucinous tumors.  
Proposed TNM Classification 
In the case of a pneumonic-type of adenocarcinoma with a single area of tumor, it is 
straightforward to apply the TNM classification as described for lung cancer in general (e.g. the T 
category determined by size, N and M determined by nodal or extrathoracic involvement).9, 19 In the case 
of multiple pulmonary sites of involvement, the T or M category should be determined by the location of 
the areas of involvement: T3 if confined to one lobe, T4 if involving different lobes in one lung, and M1a 
if involving both lungs. If the tumor involves both lungs, the T category should be designated according 
to the appropriate T category for the side with the greatest amount of tumor (i.e. size or T3 if in one lobe, 
T4 if in more than 1 lobe on that side). Because size may be difficult to determine, when the area of 
involvement extends into an adjacent lobe (as well as a discrete separate area of involvement in an 
adjacent lobe) the T4 designation should be applied (recognizing extension into another lobe). If the 
involvement is confined to a single lobe but hard to measure, a designation of T3 should be used. The 
appropriate N category is chosen that applies to all pulmonary sites of the primary tumor collectively; 
pleural/pericardial tumor nodules or distant metastases will lead to an M1a, M1b or M1c designation. The 
classification should be applied to both grossly recognizable lesions as well as those that are only 
discovered on histologic examination. A detailed histologic assessment to determine whether various 
areas are exactly matching or not is not required for pneumonic-type of lung cancer. 
We propose that the schema for application of TNM classification described for pneumonic-type 
adenocarcinoma also be used for miliary forms of adenocarcinoma. Because size of miliary involvement 
is inherently difficult to determine, miliary involvement in a single lobe should be classified as T3 
without regard to size. 
Discussion 
This paper summarizes proposals for the 8th edition of the TNM classification of malignant 
tumors for patients with lung cancer who present with multiple pulmonary sites of involvement (Table 5). 
Classification of these tumors can be challenging; the goal was to provide definitions with sufficient 
clarity to lead to consistent classification. The development of these proposals was conducted by a 
specific subcommittee of the IASLC SPFC according to a formal process involving a systematic review 
of the relevant literature, and an analysis of the IASLC database. 
Although a brief summary of background evidence is provided, full details are beyond the scope 
of this paper. A systematic review of the literature regarding the definition of 2nd primary lung cancer, 
outcomes for separate tumor nodules (intrapulmonary metastases), multifocal GG/L lung adenocarcinoma 
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and pneumonic-type of adenocarcinoma as well as an analysis of the IASLC database are provided in 
other papers.5-7 This evidence informed the proposed criteria for patterns of disease that manifest multiple 
pulmonary sites of lung cancer and the application of the stage classification system described in this 
paper. 
A system of nomenclature to classify anatomic tumor extent cannot be equated as a treatment 
guideline. Nomenclature can facilitate the discussion of how to treat patients, but patient management is 
defined by studies specifically focused on particular patients, particular treatments and the efficacy 
thereof. Furthermore, the impact of attitudes towards treatment and the prevalence of particular treatment 
approaches should not be confused with a prognostic impact that is inherent to a tumor characteristic. For 
example, separate contralateral tumor nodule(s) have been reported to have a poor prognosis. However, 
almost all of these patients have been managed non-operatively (i.e. palliatively), although good 
outcomes are reported after resection (in limited data). Hence the general prognosis may be more 
reflective of the attitude towards treatment than an inherent prognostic implication of such nodules per 
se.
5
  
Historically, classification of (and management of patients with) multiple pulmonary sites of lung 
cancer has been based on speculation primarily about how physical translocation of a malignant cell from 
one site to another might occur. However, there is now extensive data that the process of metastasis is 
highly complex, influenced not only by tumor-cell-intrinsic genetic and epigenetic determinants but also a 
complex array of tumor-host-interactions at both the primary and metastatic sites.6, 20-22 Tumor cells 
transform to mesenchymal cells and back again during the process of metastasis, exist in various states 
and in permissive niches, and there is a complex bidirectional migration between primary, metastatic and 
other sites. This is governed by multiple pathways, cell signaling, and microenvironment characteristics.6, 
20-22
 Thus, speculative rationale based on routes of physical translocation of tumor cells is refuted by 
extensive evidence. Terms such as lymphatic and hematogenous spread are based on oversimplified 
concepts and should not dictate classification or treatment of patients; furthermore they hamper 
consideration of the true determinants of metastasis. 
Classification inherently involves drawing a line of separation, and there are always borderline 
zones where the distinction becomes difficult. Furthermore, there will always be patients with unusual 
presentations that defy classification. We acknowledge these facts, but hope that the structure provided 
will allow the large majority of patients to be classified easily and consistently and that the guidance 
provided makes a “best judgment” classification easier in the particularly difficult cases. 
Conclusion 
This paper describes proposed definitions to classify tumors in patients who present with more 
than one pulmonary site of lung cancer for the 8th edition of the TNM classification. We distinguish 
several patterns of disease that exhibit multiple pulmonary sites of lung cancer. These are associated with 
different biologic behavior; defining homogeneous cohorts of tumors requires both clarity about these 
categories as well as consistent application of TNM classification rules. Specifically, these patterns of 
disease involve patients with synchronous primary lung cancers, those with a separate solid tumor 
nodule(s) (intrapulmonary metastases), multifocal lung cancer presenting as multiple nodules with ground 
glass/lepidic features, and diffuse pneumonic-type of adenocarcinoma. Synchronous primary cancers are 
classified with a T, N and M category for each tumor; separate tumor nodules result in a T3, T4 or M1a 
category depending on the separate nodule location relative to the primary tumor; multifocal GG/L 
tumors are classified by the highest T lesion, the number or m for multiple in parentheses (#/m) and an N 
and M category for all tumor nodules collectively; and for pneumonic-type adenocarcinoma the T 
component is classified by size or as T3 if in one lobe, as T4 if in 2 ipsilateral lobes and M1a if 
contralateral with a single N and M category for all sites of pulmonary involvement collectively. These 
proposals are based on a systematic review of relevant literature, extensive deliberations of an 
international multidisciplinary expert panel, and several additional levels of review. We hope this leads to 
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greater ease and consistency in classification of these tumors, while recognizing that there will always be 
areas of difficulty and tumors that are challenging to classify. We also recognize that the system will need 
to be refined as further knowledge is gained.  
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APPENDIX  
IASLC Staging and Prognostic Factors Committee 
Peter Goldstraw, Past Chair, Royal Brompton Hospital and Imperial College, London, United Kingdom; 
Ramón Rami-Porta, Chair, Hospital Universitari Mutua Terrassa, Terrassa, Spain; Hisao Asamura, Chair 
Elect, Keio University, Tokyo, Japan; David Ball, Peter MacCallum Cancer Centre, Melbourne, 
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Figures 
Figure 1: Representative Examples  
Representative examples of 4 patterns of disease which manifest multiple pulmonary sites of lung cancer.  
A. Second primary cancers. A patient with 2 primary lung cancers in the RUL. CT images of each in 
the left 2 panels, corresponding microscopic images showing an adenocarcinoma and a squamous 
carcinoma in the next 2 panels. Note that most 2nd primary cancers are of the same (not a 
different) histologic type. 
B. Separate tumor nodules. A patient with a separate tumor nodule of the same histotype as the 
index tumor. The left panels show CT images of each lesion; the right panels the corresponding 
microscopic images. 
C. Multifocal GG/L lung cancer. A patient with multifocal GG/L tumors in the right upper lobe 
(who had other GG/L tumors in other lobes). Arrows point to 2 GG/L tumors on CT in the left 2 
panels; the next 2 panels show corresponding microscopic images (both were adenocarcinoma 
with a prominent lepidic component, although with different other adenocarcinoma subtypes). 
These tumors are classified together as GG/L tumors regardless of such secondary differences. 
D. Pneumonic-type of lung cancer. A patient with pneumonic-type of lung cancer (this patient also 
had focal sites of disease in the RLL). The left panels show CT images of the RUL and RML with 
the typical regional areas with a ground glass and consolidative appearance; the next panels show 
the corresponding microscopic images. 
Adeno, adenocarcinoma; CT, computed tomography; GG/L tumors, tumors with prominent ground glass 
(imaging) or lepidic (histologic) features; MIA, minimally invasive adenocarcinoma; RLL, right lower 
lobe; RML, right middle lobe; RUL, right upper lobe; Squam, squamous cell carcinoma. 
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Tables 
Table 1: Criteria to Distinguish Second Primary vs. Related Tumors 
 
Clinical Criteria* 
Tumors may be considered second primary tumors if: 
They are clearly of a different histologic type (e.g. squamous carcinoma and adenocarcinoma) by biopsy 
 
Tumors may be considered to be arising from a single tumor source if: 
Exactly matching breakpoints are identified by comparative genomic hybridization 
 
Relative arguments that favor separate tumors: 
Different radiographic appearance or metabolic uptake 
Different biomarker pattern (driver gene mutations) 
Different rates of growth (if previous imaging is available) 
Absence of nodal or systemic metastases 
 
Relative arguments that favor a single tumor source: 
The same radiographic appearance 
Similar growth patterns (if previous imaging is available) 
Significant nodal or systemic metastases 
The same biomarker pattern (and same histotype) 
 
*A comprehensive histologic assessment is not included in clinical staging, as it requires that the entire specimen 
has been resected. 
 
Pathologic Criteria (i.e. after resection) 
Tumors may be considered second primary tumors if: 
They are clearly of a different histologic type (e.g. squamous carcinoma and adenocarcinoma) 
They are clearly different by a comprehensive histologic assessment 
Squamous carcinomas that have arisen from carcinoma in situ 
 
Tumors may be considered to be arising from a single tumor source if: 
Exactly matching breakpoints are identified by comparative genomic hybridization 
 
Relative arguments that favor separate tumors (to be considered together with clinical factors): 
Different biomarker pattern 
Absence of nodal or systemic metastases 
 
Relative arguments that favor a single tumor source (to be considered together with clinical factors): 
Matching appearance on comprehensive histologic assessment 
The same biomarker pattern 
Significant nodal or systemic metastases 
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Table 2: Criteria to Categorize a Lesion as a Separate Tumor Nodule (Intrapulmonary 
Metastasis) 
 
Clinical Criteria 
Tumors should be considered to have a separate tumor nodule(s) if: 
There is a solid lung cancer and a separate tumor nodule(s) with a similar solid appearance and with 
(presumed) matching histology 
     • This applies whether or not the lesions have been biopsied, provided there is strong suspicion that the 
lesions are histologically identical 
     • This applies whether or not there are sites of extrathoracic metastases 
  
AND provided that: 
The lesions are NOT judged to be synchronous primary lung cancers 
The lesions are NOT Multifocal GG/L Lung Cancer (multiple nodules with ground glass/lepidic features) 
or pneumonic-type of lung cancer 
 
Pathologic Criteria  
Tumors should be considered to have a separate tumor nodule (intrapulmonary metastasis) if: 
There is a separate tumor nodule(s) of cancer in the lung with a similar histologic appearance to a primary 
lung cancer 
 
AND provided that: 
The lesions are NOT judged to be synchronous primary lung cancers 
The lesions are NOT multiple foci of LPA, MIA, AIS 
AIS, adenocarcinoma in situ; GG/L, ground glass/lepidic; LPA, lepidic predominant adenocarcinoma; MIA, minimally invasive 
adenocarcinoma 
(Note that a radiographically solid appearance and the specific histologic subtype of solid adenocarcinoma denote different 
things.) 
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Table 3: Criteria to Categorize a Tumor as Multifocal GG/L Adenocarcinoma 
 
Clinical Criteria 
Tumors should be considered multifocal GG/L lung adenocarcinoma if: 
There are multiple sub-solid nodules (either pure ground glass or part-solid), with at least one suspected 
(or proven) to be cancer. 
    • This applies whether or not the nodules have been biopsied 
    • This applies if the other nodules(s) are suspected to be AIS, MIA or LPA 
    • This applies if a nodule has become >50% solid but is judged to have arisen from a GGN, provided 
there are other sub-solid nodules 
    • GGN lesions <5mm or lesions suspected to be AAH are not counted 
 
Pathologic Criteria  
Tumors should be considered multifocal GG/L lung adenocarcinoma if: 
There are multiple foci of LPA, MIA, or AIS  
    • This applies whether a detailed histologic assessment (i.e. proportion of subtypes, etc.) shows a 
matching or different appearance  
    • This applies if one lesion(s) is LPA, MIA or AIS and there are other sub-solid nodules that have not 
been biopsied 
    • This applies whether the nodule(s) are identified preoperatively or only on pathologic examination 
    • Foci of AAH are not counted 
AAH, atypical adenomatous hyperplasia, AIS, adenocarcinoma in situ; GG/L, ground glass/lepidic; LPA, lepidic predominant 
adenocarcinoma; MIA, minimally invasive adenocarcinoma 
(Note that a radiographically solid appearance and the specific histologic subtype of solid adenocarcinoma denote different 
things.) 
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Table 4: Criteria to Categorize a Tumor as a Pneumonic-Type of Adenocarcinoma 
 
Clinical Criteria 
Tumors should be considered pneumonic-type of adenocarcinoma if: 
The cancer manifests in a regional distribution, similar to a pneumonic infiltrate or consolidation.  
    • This applies whether there is one confluent area or multiple regions of disease. The region(s) may be 
confined to one lobe, in multiple lobes or bilateral, but should involve a regional pattern of 
distribution.  
    • The appearance of involved areas may be ground glass, solid consolidation or a combination thereof.  
    • This can be applied whether or not the area(s) have been biopsied when there is compelling suspicion 
of malignancy. 
 
    • This should not be applied to discrete nodules (i.e. GG/L nodules)  
    • This should not be applied to tumors causing bronchial obstruction with resultant obstructive 
pneumonia or atelectasis 
 
Pathologic Criteria  
Tumors should be considered pneumonic-type of adenocarcinoma if: 
There is diffuse distribution of adenocarcinoma throughout a region(s) of the lung, as opposed to a single 
well demarcated mass or multiple discrete well demarcated nodules. 
    • This typically involves an invasive mucinous adenocarcinoma, although a mixed mucinous and non-
mucinous pattern may occur.  
    •  The tumor may show a heterogeneous mixture of of acinar, papillary and micropapillary growth 
patterns, although it is usually lepidic predominant.  
GG/L, ground glass/lepidic 
(Note that a radiographically solid appearance and the specific histologic subtype of solid adenocarcinoma denote different 
things.) 
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Table 5: Schematic Summary of Patterns of Disease and TNM Classification of Patients 
with Lung Cancer with Multiple Pulmonary Sites of Involvement  
 
 Second Primary 
Lung Cancer 
Multifocal 
GG/L Nodules 
Pneumonic-Type 
of Adenocarcinoma 
Separate 
Tumor Nodule 
Imaging 
Features 
Two or more distinct 
masses with imaging 
characteristic of lung 
cancer (e.g. spiculated) 
Multiple ground glass 
or part-solid nodules 
Patchy areas of ground 
glass and consolidation 
Typical lung cancer 
(e.g. solid, spiculated) 
with separate solid 
nodule  
Pathologic 
Features 
Different histotype or 
different morphology 
by comprehensive 
histologic assessment 
Adenocarcinomas with 
prominent lepidic 
component (typically 
varying degrees of 
AIS, MIA, LPA)  
Same histology 
throughout (most often 
invasive mucinous 
adenocarcinoma)  
Distinct masses with 
the same morphology 
by comprehensive 
histologic assessment 
TNM Classi-
fication 
Separate cTNM and 
pTNM for each cancer 
T based on highest T 
lesion with (#/m) 
indicating multiplicity; 
single N and M 
T based on size  or T3 if 
in single lobe, T4 or 
M1a if in different ipsi- 
or contralateral lobes;  
single N and M 
Location of separate 
nodule relative to 
primary site 
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